Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
ResMed (NASDAQ:RMD), a $37.6 billion medical equipment company trading near its 52-week high, saw Chief Executive Officer Michael J. Farrell sell 8,009 shares of company stock on July 7, 2025, for approximately $2.06 million. The sales were executed in multiple trades at prices ranging from $255.6 to $258.22. According to InvestingPro analysis, the stock is currently trading close to its Fair Value. On the same day, Farrell also exercised options to acquire 8,009 shares of ResMed stock at a price of $101.64, for a total value of $814034.
Following the sale, Farrell directly owns 455,503 shares of ResMed.
The option exercise relates to options that first became exercisable on November 11, 2019, and vest at a rate of 1/3 per year.
The reported transactions were executed under a Rule 10b5-1 plan adopted on October 31, 2024.
In other recent news, ResMed’s third-quarter results aligned with expectations, prompting Citi analysts to raise the stock’s price target to AUD45.00 from AUD44.00 while maintaining a Buy rating. This adjustment reflects anticipated improvements in earnings per share for fiscal years 2025 to 2027. UBS analyst Marcus Curley also reaffirmed a Buy rating with a price target of $285.00, following promising results from Apnimed’s Phase 3 clinical trial for a new obstructive sleep apnea treatment. Stifel analysts maintained a Hold rating with a $240.00 price target, noting that while device sales fell short, mask sales exceeded expectations, resulting in a 9% growth in constant currency. Despite this, Stifel expressed concerns about the potential impact of GLP-1 medications on future revenue and EPS estimates.
KeyBanc maintained an Overweight rating for ResMed, highlighting limited innovation from the company at a recent industry event, although they noted significant developments from competitor React Health. Citi analysts emphasized ResMed’s strong free cash flow and balance sheet, projecting a 15% compound annual growth rate in earnings per share from fiscal year 2024 to 2027. They also mentioned that GLP-1 medications have not yet impacted ResMed’s business, though their future effects remain uncertain. Meanwhile, ResMed’s management announced a nearly complete exemption from certain tariffs, providing short-term relief for some investors. As the company continues to navigate these developments, analysts and investors alike remain attentive to the potential impacts on ResMed’s market position and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.